The PCa Tumor Microenvironment

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Cancer Microenvironment

• Publication date

  2011-07-05

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s12307-011-0073-8PMID 21728070PMCID PMC3234329
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interleukin-6: A multifunctional targetable cytokine in human prostate cancer

  2012cited by this paper
• Endothelial progenitor cells and circulating endothelial cells in early prostate cancer: A comparison with plasma vascular markers

  2011cited by this paper
• IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR

  2011cited by this paper
• Infiltration of tumour‐associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer

  2011cited by this paper
• Use of macrophages to target therapeutic adenovirus to human prostate tumors.

  2011cited by this paper
• (-)-Oleocanthal as a c-Met inhibitor for the control of metastatic breast and prostate cancers.

  2011cited by this paper
• Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma.

  2011cited by this paper
• Antiangiogenic therapy: impact on invasion, disease progression, and metastasis

  2011cited by this paper
• Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow.

  2011cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• Targeting prostate cancer angiogenesis through metastasis‐associated protein 1 (MTA1)

  2011cited by this paper
• Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

  2011cited by this paper
• The Role of RANK-Ligand Inhibition in Cancer: The Story of Denosumab

  2011cited by this paper
• Macrophages induce neuroendocrine differentiation of prostate cancer cells via BMP6‐IL6 Loop

  2011cited by this paper
• The functional role of reactive stroma in benign prostatic hyperplasia.

  2011cited by this paper
• Altered TGF-β signaling in a subpopulation of human stromal cells promotes prostatic carcinogenesis.

  2011cited by this paper
• Role of the endothelin axis and its antagonists in the treatment of cancer

  2011cited by this paper
• Infection, inflammation and prostate carcinogenesis.

  2011cited by this paper
• Cellular senescence: putting the paradoxes in perspective.

  2011cited by this paper
• The first Tianjin, China forum on tumor microenvironment.

  2011cited by this paper
• Metronomic chemotherapy: principles and lessons learned from applications in the treatment of metastatic prostate cancer.

  2010cited by this paper
• VEGF and prostatic cancer: a systematic review

  2010cited by this paper
• Horizon scanning for novel therapeutics for the treatment of prostate cancer.

  2010cited by this paper
• Denosumab: in cancer treatment-induced bone loss.

  2010cited by this paper
• BMS-777607, a Small-Molecule Met Kinase Inhibitor, Suppresses Hepatocyte Growth Factor–Stimulated Prostate Cancer Metastatic Phenotype In vitro

  2010cited by this paper
• TGF-β Pathway as a Therapeutic Target in Bone Metastases

  2010cited by this paper
• The role of TRPC6 in HGF-induced cell proliferation of human prostate cancer DU145 and PC3 cells.

  2010cited by this paper
• Tgf-Beta pathway as a therapeutic target in bone metastases.

  2010cited by this paper
• Prognostic value of IL-6 in localized prostatic cancer.

  2010cited by this paper
• Role of monocyte‐lineage cells in prostate cancer cell invasion and tissue factor expression

  2010cited by this paper
• Metronomic chemotherapy: new rationale for new directions

  2010cited by this paper
• Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.

  2010cited by this paper
• Intensity of stromal changes predicts biochemical recurrence-free survival in prostatic carcinoma

  2010cited by this paper
• Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features.

  2010cited by this paper
• Characterization of phosphoglycerate kinase-1 expression of stromal cells derived from tumor microenvironment in prostate cancer progression.

  2010cited by this paper
• Shedding of RANKL by tumor-associated MT1-MMP activates Src-dependent prostate cancer cell migration.

  2010cited by this paper
• FGF signalling in prostate development, tissue homoeostasis and tumorigenesis.

  2010cited by this paper
• The essence of senescence.

  2010cited by this paper
• Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel.

  2010cited by this paper
• HGF-induced invasion by prostate tumor cells requires anterograde lysosome trafficking and activity of Na+-H+ exchangers

  2010cited by this paper
• Cancer-associated fibroblasts enhance the gland-forming capability of prostate cancer stem cells.

  2010cited by this paper
• In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice.

  2010cited by this paper
• Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression.

  2010cited by this paper
• Biology and clinical observations of regulatory T cells in cancer immunology.

  2010cited by this paper
• Zibotentan for the treatment of castrate-resistant prostate cancer

  2010cited by this paper
• Sorafenib's inhibition of prostate cancer growth in transgenic adenocarcinoma mouse prostate mice and its differential effects on endothelial and pericyte growth during tumor angiogenesis.

  2010cited by this paper
• Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer

  2010cited by this paper
• The CXCR4/SDF-1 chemokine axis: a potential therapeutic target for bone metastases?

  2010cited by this paper
• Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth.

  2010cited by this paper
• Angiogenesis inhibitors in prostate cancer therapy.

  2010cited by this paper
• Osteoclast-Derived Matrix Metalloproteinase-9 Directly Affects Angiogenesis in the Prostate Tumor–Bone Microenvironment

  2010cited by this paper
• Pericyte coverage decreases invasion of tumour cells into blood vessels in prostate cancer xenografts

  2009cited by this paper
• Circulating prediagnostic interleukin‐6 and C‐reactive protein and prostate cancer incidence and mortality

  2009cited by this paper
• Modulation of prostate cancer cell gene expression by cell-to-cell contact with bone marrow stromal cells or osteoblasts

  2009cited by this paper
• Endothelin-1 inhibits prostate cancer growth in vivo through vasoconstriction of tumor-feeding arterioles

  2009cited by this paper
• Targeting TGF-β in prostate cancer: therapeutic possibilities during tumor progression

  2009cited by this paper
• Protease‐activated receptor‐1 is upregulated in reactive stroma of primary prostate cancer and bone metastasis

  2009cited by this paper
• Cutting Edge: Depletion of Foxp3+ Cells Leads to Induction of Autoimmunity by Specific Ablation of Regulatory T Cells in Genetically Targeted Mice1

  2009cited by this paper
• Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.

  2009cited by this paper
• Validation of a Standardized Method for Enumerating Circulating Endothelial Cells and Progenitors: Flow Cytometry and Molecular and Ultrastructural Analyses

  2009cited by this paper
• Targeting TGF-beta in prostate cancer: therapeutic possibilities during tumor progression.

  2009cited by this paper
• Stroma-epithelium crosstalk in prostate cancer.

  2009cited by this paper
• The role of Dickkopf-1 in bone development, homeostasis, and disease.

  2009cited by this paper
• Keratinocyte‐derived chemokine induces prostate epithelial hyperplasia and reactive stroma in a novel transgenic mouse model

  2009cited by this paper
• Denosumab in men receiving androgen-deprivation therapy for prostate cancer.

  2009cited by this paper
• Extratumoral macrophages promote tumor and vascular growth in an orthotopic rat prostate tumor model.

  2009cited by this paper
• Mechanism of bone metastasis: the role of osteoprotegerin and of the host-tissue microenvironment-related survival factors.

  2009cited by this paper
• CCL2 and Interleukin-6 Promote Survival of Human CD11b+ Peripheral Blood Mononuclear Cells and Induce M2-type Macrophage Polarization*

  2009cited by this paper
• Pretreatment frequency of circulating IL‐17+CD4+ T‐cells, but not Tregs, correlates with clinical response to whole‐cell vaccination in prostate cancer patients

  2009cited by this paper
• Induction of proinflammatory response in prostate cancer epithelial cells by activated macrophages.

  2009cited by this paper
• Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells.

  2008cited by this paper
• Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms.

  2008cited by this paper
• Predictive Value of Plasma Hepatocyte Growth Factor/Scatter Factor Levels in Patients with Clinically Localized Prostate Cancer

  2008cited by this paper
• Enhanced Functionality of CD4+CD25highFoxP3+ Regulatory T Cells in the Peripheral Blood of Patients with Prostate Cancer

  2008cited by this paper
• Phenotypic Analysis of Prostate-Infiltrating Lymphocytes Reveals TH17 and Treg Skewing

  2008cited by this paper
• Osteoclasts Are Active in Bone Forming Metastases of Prostate Cancer Patients

  2008cited by this paper
• Receptor activator of nuclear factor-kappaB ligand (RANKL) as a novel prognostic marker in prostate carcinoma.

  2008cited by this paper
• Inflammation and prostate cancer.

  2008cited by this paper
• Elevated epithelial expression of interleukin-8 correlates with myofibroblast reactive stroma in benign prostatic hyperplasia.

  2008cited by this paper
• Circulating endothelial cells as biomarkers of prostate cancer

  2008cited by this paper
• Mcl-1 is regulated by IL-6 and mediates the survival activity of the cytokine in a model of late stage prostate carcinoma.

  2008cited by this paper
• Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages

  2008cited by this paper
• Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor

  2008cited by this paper
• Pigment epithelium-derived factor and interleukin-6 control prostate neuroendocrine differentiation via feed-forward mechanism.

  2008cited by this paper
• Prostate stem cells and benign prostatic hyperplasia

  2008cited by this paper
• Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone‐refractory prostate cancer

  2008cited by this paper
• Wnt signaling and prostate cancer.

  2008cited by this paper
• RANKL acts directly on RANK‐expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes

  2008cited by this paper
• A glycolytic mechanism regulating an angiogenic switch in prostate cancer.

  2007cited by this paper
• Molecular targets in pulmonary fibrosis: the myofibroblast in focus.

  2007cited by this paper
• Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases

  2007cited by this paper
• CD8+ Foxp3+ Regulatory T Cells Mediate Immunosuppression in Prostate Cancer

  2007cited by this paper
• Targeting uPA/uPAR in prostate cancer.

  2007cited by this paper
• Hepatocyte growth factor up-regulates the expression of the bone morphogenetic protein (BMP) receptors, BMPR-IB and BMPR-II, in human prostate cancer cells.

  2007cited by this paper
• Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases

  2007cited by this paper
• Induction of hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer.

  2007cited by this paper
• Macrophages from irradiated tumors express higher levels of iNOS, arginase-I and COX-2, and promote tumor growth.

  2007cited by this paper
• PTHrP‐induced MCP‐1 production by human bone marrow endothelial cells and osteoblasts promotes osteoclast differentiation and prostate cancer cell proliferation and invasion in vitro

  2007cited by this paper
• Skeletal metastasis: Established and emerging roles of parathyroid hormone related protein (PTHrP)

  2007cited by this paper
• The myofibroblast: one function, multiple origins.

  2007cited by this paper

• Engineering the bone metastatic prostate cancer niche through a microphysiological system to report patient-specific treatment response

  2025cites this paper
• Ferroptosis-related gene signature predicts prognosis and immune microenvironment in prostate cancer

  2024cites this paper
• Glucocorticoid treatment influences prostate cancer cell growth and the tumor microenvironment via altered glucocorticoid receptor signaling in prostate fibroblasts

  2023cites this paper
• Synthesis and evaluation of a multifunctional probe with a high affinity for prostate-specific membrane antigen (PSMA) and bone.

  2022cites this paper
• Application of Anti-Inflammatory Agents in Prostate Cancer

  2020cites this paper
• Androgen receptor signalling in macrophages promotes TREM-1-mediated prostate cancer cell line migration and invasion

  2020cites this paper
• A Multiparametric MRI for the Classification and Grading of Prostate Cancer

  2019cites this paper
• Multiple Roles of Osteocytes in Bone-Associated Cancers

  2019cites this paper
• Inflammation and Prostate Cancer.

  2018cites this paper
• Cell & Molecular Biology of Prostate Cancer

  2018cites this paper
• The bone microenvironment promotes tumor growth and tissue perfusion compared with striated muscle in a preclinical model of prostate cancer in vivo

  2018cites this paper
• Immunodiagnostics and Immunotherapy Possibilities for Prostate Cancer.

  2018cites this paper
• Combining Desmopressin and Docetaxel for the Treatment of Castration-Resistant Prostate Cancer in an Orthotopic Model

  2018cites this paper
• Immortalized Cancer-associated Fibroblasts Promote Prostate Cancer Carcinogenesis, Proliferation and Invasion.

  2017cites this paper
• Practical aspects of prostate MRI: hardware and software considerations, protocols, and patient preparation

  2016cites this paper
• Prediction of treatment efficacy for prostate cancer using a mathematical model

  2016cites this paper
• Association between genetic polymorphisms of MMP8 and the risk of steroid-induced osteonecrosis of the femoral head in the population of northern China

  2016cites this paper
• Development of Novel Nanomedicines for Treatment of Primary and Metastatic Prostate Cancer.

  2016cites this paper
• of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients

  2015cites this paper
• TLR 9-Targeted STAT 3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients

  2015cites this paper
• 1 Biology of Human Tumors Q 1 2 T-box Transcription Factor Brachyury Is Associated with 3 Prostate Cancer Progression and Q 2 Aggressiveness 4 5

  2015cites this paper
• AWARD NUMBER: W81XWH-12-1-0132 TITLE: CpG-STAT3siRNA for Castration-Resistant Prostate Cancer Therapy

  2015cites this paper
• Erratum to “Inflammation and Its Role in Prostate Cancer” [Journal of Cancer Therapy 5 (2014) 836-844]

  2015cites this paper
• TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients

  2015cites this paper
• Recent advances in bone-targeted therapies of metastatic prostate cancer.

  2014cites this paper
• Identification of genes regulating migration and invasion using a new model of metastatic prostate cancer

  2014cites this paper
• T-box Transcription Factor Brachyury Is Associated with Prostate Cancer Progression and Aggressiveness

  2014cites this paper
• Inflammation and Its Role in Prostate Cancer

  2014cites this paper
• Inflammatory Microenvironment in Prostate Carcinogenesis

  2013cites this paper
• Trimethoxy‐Resveratrol and Piceatannol Administered Orally Suppress and Inhibit Tumor Formation and Growth in Prostate Cancer Xenografts

  2013cites this paper
• Expression of Id proteins is regulated by the Bcl-3 proto-oncogene in prostate cancer

  2013cites this paper
• Understanding and targeting osteoclastic activity in prostate cancer bone metastases.

  2013cites this paper
• Regulation of epithelial plasticity by miR-424 and miR-200 in a new prostate cancer metastasis model

  2013cites this paper
• Cancer immunotherapy: a paradigm shift for prostate cancer treatment

  2012cites this paper